Clinical Trial Update: Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS [Phase 3]

View source ↗

Summary

Phase 3 trial comparing certolizumab pegol to placebo in nonradiographic axial spondyloarthritis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Nonradiographic Axial Spondyloarthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB BIOSCIENCES GmbH | Conditions: Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2020-08-17